Aerosol Drug Delivery (Egan's Chapter 40)

Clinical Pharmacology and Classes of Aerosolized Medications

  • Primary Therapeutic Drug Classes Delivered via Aerosol:

    • Bronchodilators: Relax and dilate airway smooth muscle to open bronchial passages constricted by bronchospasm or reactive airway disease.
    • Inhaled Corticosteroids (ICS): Treat underlying airway inflammation, reduce mucosal edema, and suppress late-phase allergic responses.
    • Mucus-Controlling Agents (Mucolytics): Alter the biophysical properties of respiratory secretions to enhance airway clearance and expectoration.
    • Inhaled Anti-Infective Agents: Target viral, bacterial, and fungal pathogens directly within the pulmonary parenchyma and tracheobronchial tree while minimizing systemic toxicity.
  • Autonomic and Airway Receptor Physiology:

    • α1\alpha_1 Receptors: Located primarily on vascular smooth muscle; stimulation causes vasoconstriction, which elevates blood pressure and decongests swollen airway mucosa.
    • β1\beta_1 Receptors: Located primarily on cardiac tissue; stimulation increases chronotropy (heart rate) and inotropy (contractility).
    • β2\beta_2 Receptors: Located on bronchial smooth muscle; stimulation triggers intracellular cyclic adenosine monophosphate (cAMP\text{cAMP}) production, resulting in smooth muscle relaxation and bronchodilation.
    • Muscarinic (M3\text{M}_3) Receptors: Located on parasympathetic postganglionic airway smooth muscle and submucosal glands; stimulation causes bronchoconstriction and glandular mucus secretion. Anticholinergic drugs block M3\text{M}_3 receptors to prevent bronchoconstriction.
  • Short-Acting Bronchodilators (SABAs and SAMAs):

    • Albuterol (SABA / β2-agonist\beta_2\text{-agonist}):
    • Brand Names: ProAir, Ventolin.
    • Available Formulations: Nebulized solution (2.5 mg2.5\,\text{mg} in 0.5 mL0.5\,\text{mL} unit-dose or concentrated solutions diluted with normal saline), pressurized metered-dose inhaler (pMDI), and dry powder inhaler (DPI, such as ProAir RespiClick).
    • Levalbuterol (Xopenex): The single (R)-enantiomer(R)\text{-enantiomer} of albuterol; acts as a selective short-acting β2-agonist\beta_2\text{-agonist}.
    • Ipratropium Bromide (Atrovent): Short-acting muscarinic antagonist (SAMA / anticholinergic) that blocks bronchoconstriction mediated via M3\text{M}_3 receptor pathways.
    • Available Formulations: Nebulized solution (0.5 mg0.5\,\text{mg} in 2.5 mL2.5\,\text{mL}) and pMDI.
  • Fixed-Dose Short-Acting Combination Medications:

    • DuoNeb: Nebulized solution combining Albuterol (2.5 mg2.5\,\text{mg}) and Ipratropium Bromide (0.5 mg0.5\,\text{mg}) for synergistic bronchodilation.
    • Combivent Respimat: Soft Mist Inhaler (SMI) delivering a fixed combination of Albuterol and Ipratropium Bromide without chemical propellants.
  • Long-Acting Bronchodilators (LABAs and LAMAs):

    • Formoterol (Perforomist): Long-acting β2-agonist\beta_2\text{-agonist} (LABA) formulated for nebulization.
    • Tiotropium Bromide (Spiriva): Long-acting muscarinic antagonist (LAMA) delivered via HandiHaler DPI or Respimat SMI.
    • Umeclidinium (Incruse Ellipta): Once-daily LAMA delivered via the Ellipta DPI (55 μg55\,\mu\text{g} per blister).
  • Inhaled Corticosteroids (ICS):

    • Common ICS Formulations:
    • Fluticasone propionate (Flovent).
    • Budesonide (Pulmicort).
    • Beclomethasone dipropionate (QVAR, QVAR RediHaler).
    • Clinical Practice Rule: Drugs ending in the suffix "-sone" or "-nide" designate corticosteroid agents.
    • Adverse Effects and Patient Instructions: Localized deposition in the oropharynx suppresses mucosal immunity and alters normal flora, predisposing patients to oral candidiasis (Candida albicans, or thrush) and dysphonia. Patients must rinse their mouth thoroughly with water and spit it out following each ICS administration.
  • Combination Maintenance Formulations:

    • Steroid + Long-Acting β2-Agonist\beta_2\text{-Agonist} (ICS/LABA): Advair (Fluticasone/Salmeterol), Breo Ellipta (Fluticasone furoate/Vilanterol), Symbicort (Budesonide/Formoterol).
    • Long-Acting β2-Agonist\beta_2\text{-Agonist} + Long-Acting Muscarinic Antagonist (LABA/LAMA): Anoro Ellipta (Vilanterol/Umeclidinium), Stiolto Respimat (Olodaterol/Tiotropium).
    • Triple Therapy (ICS + LABA + LAMA): Trelegy Ellipta (Fluticasone furoate/Umeclidinium/Vilanterol).
    • Clinical Advantage: Simplifies medication regimens, improves adherence, and provides combined anti-inflammatory and dual-pathway bronchodilator coverage.
  • Sequence of Multi-Drug Delivery:

    • First: Bronchodilator (SABA\text{SABA} or LABA\text{LABA}, e.g., four times daily [QID] or twice daily [BID]) to open airways and reduce airway resistance.
    • Second: Mucus-controlling agent (e.g., BID) to mobilize secretions through patent airways.
    • Third: Anti-infective agent (e.g., BID) to ensure maximum peripheral penetration and contact with infected tissue.

Principles of Aerosol Physics and Particle Dynamics

  • Core Definitions:

    • Aerosol: A suspension of solid or liquid particles in a carrier gas.
    • Medical Aerosols: Generated via pneumatic nebulizers, ultrasonic generators, vibrating mesh devices, or inhalers (pMDIs, SMIs, DPIs).
    • Primary Clinical Uses: Administration of bland water/saline solutions to hydrate secretions or induce sputum, and targeted pharmacological delivery to the nose, throat, conducting airways, or alveoli.
    • Aerosol Output: The mass of fluid or drug contained within the aerosol generated by an aerosol production device.
    • Emitted Dose: The mass of drug exiting the mouthpiece or patient interface of a nebulizer or inhaler as an aerosol.
    • Deposition Fraction: The proportion of the emitted dose that successfully deposits in target pulmonary structures; a substantial fraction of emitted aerosol is lost to device clearance, oropharyngeal impaction, or exhalation.
  • Particle Sizing and Mass Median Aerodynamic Diameter (MMAD):

    • Aerosol particle size depends on the physical characteristics of the liquid formulation, the generation technique, and environmental conditions (temperature, relative humidity).
    • Measurement: Laboratory analysis (such as cascade impaction or laser diffraction) is the only reliable method for characterizing aerosol particle distributions.
    • Mass Median Aerodynamic Diameter (MMAD): The diameter around which 50%50\% of the aerosol mass consists of larger particles and 50%50\% consists of smaller particles.
  • Targeted Deposition by Particle Size (Rule of Thumb):

    • Upper Airway (Nose, Larynx, Trachea): 5 μm to >50 μm5\,\mu\text{m}\text{ to } >50\,\mu\text{m}.
    • Lower Conducting Airways: 2 μm to 5 μm2\,\mu\text{m}\text{ to } 5\,\mu\text{m}.
    • Parenchyma (Alveolar Region): 1 μm to 3 μm1\,\mu\text{m}\text{ to } 3\,\mu\text{m}.
    • Deep Alveolar Penetration (Brownian Diffusion): <0.1 μm<0.1\,\mu\text{m}.
    • Clearance Zone (0.5 μm to 1 μm0.5\,\mu\text{m}\text{ to } 1\,\mu\text{m}): Particles in this range have sufficient mass to avoid diffusion but remain stable in suspension, causing up to 80%80\% or more to be exhaled directly without deposition.
  • Mechanisms of Aerosol Deposition:

    • Inertial Impaction:
    • Occurs when suspended moving particles possess excessive momentum to navigate directional changes in the airflow airstream, colliding with airway walls.
    • Directly proportional to particle mass and velocity (Momentum=mass×velocity\text{Momentum} = \text{mass} \times \text{velocity}.
    • Primary deposition mechanism for particles >5 μm>5\,\mu\text{m}.
    • Prominent at anatomical bifurcations (carina, early airway divisions) and is amplified when inspiratory flow rates exceed 30 L/min30\,\text{L/min}.

Inertial impaction at an airway bifurcation

  • Gravitational Sedimentation:
    • Occurs when aerosol particles settle out of suspension due to gravitational pull.
    • Primary deposition mechanism for particles sized 1 μm to 5 μm1\,\mu\text{m}\text{ to } 5\,\mu\text{m}.
    • Settling velocity is greater for larger particles with slow linear velocities.
    • Performing an end-inspiratory breath-hold of 10 seconds10\,\text{seconds} increases peripheral aerosol deposition by approximately 10%10\%.
    • Upright positioning optimizes gravitational sedimentation across dependent lung regions.

Effect of mass on particle size: sedimentation versus diffusion

  • Brownian Diffusion:

    • Affects submicron particles (<3 μm<3\,\mu\text{m}, predominantly <1 μm<1\,\mu\text{m} and <0.1 μm<0.1\,\mu\text{m}) in non-turbulent alveolar airspaces where bulk flow ceases.

    • Particles possess minimal mass and are displaced by random collisions with ambient gas molecules, causing collisions with alveolar epithelial surfaces.

    • Aerosol Aging:

  • Aerosols are dynamic, non-equilibrium suspensions. Individual particles change size over time through:

    • Evaporation: Reduces particle size in dry, warm environments, shifting deposition more distally.

    • Hygroscopic Water Absorption: Particles absorb moisture in high-humidity conditions (100%100\% relative humidity in the respiratory tract), expanding in diameter and depositing more proximally than predicted by initial room-air measurements.

    • Coalescence: Small colliding droplets combine into larger droplets and rapidly fall out of suspension.

    • Patient Breathing Pattern Variables Influencing Deposition:

  • Inspiratory Flow Rate: High flow (>30 L/min>30\,\text{L/min}) increases upper airway inertial impaction; slow, laminar flow promotes peripheral penetration.

  • Inhaled Volume (Tidal Volume, VTV_T): Larger volumes carry aerosol deeper into the peripheral tracheobronchial tree.

  • Respiratory Frequency: Rapid, shallow tachypnea limits transit time, increasing dead-space loss and exhalation of unimpacted particles.

  • Inspiratory-to-Expiratory (I:EI:E) Ratio: Prolonged inspiratory time expands the transit window for peripheral sedimentation.

  • Breath-Hold Maneuver: A 10-second10\text{-second} pause at total lung capacity maximizes settling in the small conducting airways and alveoli.

  • Airway Obstruction: Severe bronchospasm, secretions, and mucosal thickening increase turbulence and focal impaction in central airways, reducing peripheral dose delivery.

Clinical Advantages, Disadvantages, and Hazards of Aerosol Therapy

  • Clinical Advantages:

    • Doses administered via aerosol are markedly smaller than equivalent therapeutic oral or intravenous doses.
    • Drug onset is rapid (3 to 5 minutes3\text{ to } 5\,\text{minutes} for fast-acting bronchodilators) compared to oral dosing.
    • Delivers medication directly to targeted pulmonary receptors, minimizing systemic absorption and adverse side effects.
    • Route is non-invasive, painless, and well-tolerated by patients across age ranges.
  • Clinical Disadvantages:

    • High incidence of improper patient technique with hand-actuated devices.
    • Wide variability among device interfaces confuses patients and healthcare providers.
    • The precise delivered dose to the lower airway fluctuates based on patient breathing patterns, airway caliber, and device efficiency.
  • Therapeutic Hazards and Complications:

    • Infection:
    • Contaminated aerosol generators and tubing act as vectors for nosocomial pneumonia.
    • Primary sources: Inadequate cleaning, non-sterile wash water, handling multi-dose vials, and leaving residual fluid in medication cups between treatments.
    • Bioaerosol vs. Medical Aerosol Distinction: When delivered properly using sterile medications and clean interfaces, medical aerosols generated by nebulizers do not create bioaerosols and do not increase the transmission risk of airborne respiratory pathogens. Medical aerosol therapy should not be withheld from patients with airborne respiratory infections.
    • Secondhand Environmental Exposure:
    • Up to 70%70\% of aerosol generated by continuous, unvented jet nebulizers discharges directly into ambient room air.
    • Poses health risks to clinical staff and family members from occupational exposure to bronchodilators, antibiotics, and teratogenic/mutagenic agents (e.g., Ribavirin, Pentamidine).
    • Airway Hyperreactivity:
    • Cold or high-density aerosols (e.g., ultrasonic mist, sterile water) can trigger bronchospasm, coughing, and increased airway resistance in hyperreactive patients.
    • Fluid and Electrolyte Imbalances from Bland Aerosols:
    • Nebulization of excessive sterile water can cause systemic overhydration, particularly in neonates and infants.
    • Excessive administration of hypertonic saline can lead to systemic hypernatremia.
    • Copious secretion mobilization requires active clearing; patients with poor cough reflexes need airway clearance therapy to prevent acute obstruction.
    • Ocular Irritation:
    • Poorly fitting face masks direct aerosol plumes into the eyes.
    • Accidental ocular deposition of anticholinergics (such as Ipratropium Bromide) induces pupillary dilation, blurred vision, and can exacerbate angle-closure glaucoma.
  • Engineering Controls for Toxic Aerosol Administration:

    • Respirgard II Nebulizer System: Developed specifically for administering Pentamidine; incorporates two one-way valves and a high-efficiency 360∘360^\circ expiratory filter to contain exhaled particles.
    • Negative Pressure Isolation Rooms: Must be utilized when administering hazardous medications (Pentamidine, Ribavirin). Requires a minimum of 66 air exchanges per hour, with air vented directly outside or filtered through certified HEPA scrubbers.

Small-Volume and Large-Volume Pneumatic Jet Nebulizers

  • Operating Principles of Pneumatic Jet Nebulizers:
    • Powered by high-pressure gas (50 psig50\,\text{psig} or portable air compressors) routed through a restricted orifice (jet nozzle).
    • The high-velocity gas jet generates a localized drop in lateral pressure (Bernoulli principle), drawing liquid medication up capillary feed tubes from the reservoir.
    • The emerging liquid stream is sheared into an unstable liquid sheet that breaks into droplets.
    • The primary droplet stream is directed against baffles, which remove large droplets (>5 μm>5\,\mu\text{m}) via inertial impaction and return them to the reservoir. Smaller, respirable particles remain suspended in the gas stream and exit the device.

Pneumatic jet nebulizer design and baffle mechanism

  • Dead Volume (Residual Drug Volume):

    • The volume of medication trapped within the baffles, internal walls, and reservoir bottom at the end of nebulization when the device begins to sputter.
    • In a standard 3 mL3\,\text{mL} fill, residual volume ranges from 0.5 mL to >2.2 mL0.5\,\text{mL}\text{ to }>2.2\,\text{mL} (up to two-thirds of the total loaded dose is not delivered).
    • Tilting the nebulizer increases dead volume and halts aerosolization prematurely; devices must be maintained vertically.
    • Increasing total fill volume from 3 mL3\,\text{mL} to 4–5 mL4\text{–}5\,\text{mL} with diluent reduces the fraction of active drug trapped in the dead space, increasing delivered mass at the expense of longer treatment times.
  • Gas Flow and Volume Interactions:

    • Operating gas flow is inversely related to droplet size and nebulization time:
    • Higher flow (8–10 L/min8\text{–}10\,\text{L/min}): Produces smaller MMAD droplets and shortens treatment time.
    • Lower flow (<6 L/min<6\,\text{L/min}): Produces larger droplets and prolongs treatment time.
    • Standard manufacturer driving gas flow recommendations: 6 L/min to 10 L/min6\,\text{L/min}\text{ to } 10\,\text{L/min}.
  • Carrier Gas Density and Heliox Correction:

    • Driving nebulizers with lower-density gases reduces turbulent impaction, producing smaller droplets with improved peripheral deposition.
    • When driving a jet nebulizer with Helium-Oxygen (Heliox\text{Heliox} 80:2080:20 ratio, factor 1.81.8), higher flow rates are required to achieve adequate shear pressures:
    • To deliver a desired flow rate of 7 L/min7\,\text{L/min} using an oxygen flowmeter calibrated for 80:2080:20 Heliox:       Flowmeter Setting=7 L/min×1.8=12.6 L/min≈13 L/min\text{Flowmeter Setting} = 7\,\text{L/min} \times 1.8 = 12.6\,\text{L/min} \approx 13\,\text{L/min}
  • Jet Small-Volume Nebulizer (SVN) Classifications:

    • Continuous Nebulizer with Simple Reservoir:
    • Most commonly used and least expensive.
    • Operates continuously throughout inspiration, expiration, and breath-holds.
    • Highly inefficient: <10%<10\% of loaded drug deposits in adult lungs; 0.5%0.5\% or less deposits in neonates and infants.
    • Attaching a 6-inch6\text{-inch} corrugated reservoir tube to the expiratory limb captures a portion of aerosol generated during exhalation for the subsequent breath.
    • Breath-Enhanced Nebulizer (BEN, e.g., Pari LC):
    • Generates aerosol continuously but uses a system of inspiratory and expiratory one-way valves.
    • Patient inhalation draws ambient air through a top inspiratory valve, increasing airflow through the nebulizing chamber and boosting aerosol delivery during inspiration.
    • On exhalation, the one-way inlet valve closes while an expiratory valve opens, directing exhaled gas away from the generation zone and reducing ambient medication loss.

Breath-enhanced nebulizer mechanism of action

  • Breath-Actuated Nebulizer (BAN, e.g., AeroEclipse):

    • Synchronizes aerosol generation with patient inspiratory effort using a mechanical or electronic breath-actuated valve mechanism.

    • Halts aerosolization during expiration, eliminating ambient waste.

    • Inhaled dose increases up to threefold compared to continuous SVNs.

    • Features a green feedback button that moves during inhalation to verify proper actuation and technique.

    • Can be switched to continuous nebulization mode if the patient cannot trigger the breath-actuation mechanism.

    • Standard Clinical Technique for SVN Delivery:

  • Assess the patient (clinical symptoms, vitals, auscultation, peak flow, and %FEV1\%\text{FEV}_1).

  • Select an interface: Mouthpiece is preferred to bypass nasal filtering; a fitted aerosol mask is used for patients unable to maintain a mouthpiece seal.

  • Inspect and assemble the device; place the prescribed medication dose in the reservoir (add sterile normal saline diluent to achieve a 3–5 mL3\text{–}5\,\text{mL} total fill volume if using concentrated or multidose solutions).

  • Connect the nebulizer to compressed air or oxygen source and set flow to 6–10 L/min6\text{–}10\,\text{L/min}.

  • Coach the patient to sit upright and breathe slowly and deeply through the mouth at normal tidal volume (VTV_T), incorporating periodic breath-holds.

  • Continue treatment until the device sputters intermittently (≈8–12 minutes\approx 8\text{–}12\,\text{minutes}).

  • Tap the nebulizer walls gently to return droplets to the reservoir bottom.

  • Rinse the device with sterile water, air dry on an absorbent towel, and store in a clean bag between uses; discard or replace per institutional protocol.

  • Reassess patient vitals, breath sounds, adverse reactions, and objective flow parameters (PEF\text{PEF}, %FEV1\%\text{FEV}_1).

    • Large-Volume Jet Nebulizers:
  • HEART and HOPE Nebulizers:

    • Reservoirs exceed 200 mL200\,\text{mL}.
    • Deliver continuous bronchodilator therapy (CBT) for severe, refractory status asthmaticus.
    • Produce aerosol with an MMAD of 2.2 μm to 3.5 μm2.2\,\mu\text{m}\text{ to } 3.5\,\mu\text{m}.
  • Small Particle Aerosol Generator (SPAG-2):

    • Specialized large-volume nebulizer holding up to 300 mL300\,\text{mL} of solution.
    • Features a drying chamber with separate air flowmeters to evaporate droplet water content, reducing final particle MMAD to approximately 1.3 μm1.3\,\mu\text{m}.
    • Used exclusively for administering the antiviral agent Ribavirin (Virazole) to pediatric patients with severe Respiratory Syncytial Virus (RSV).

Ultrasonic and Vibrating Mesh Nebulizers

  • Ultrasonic Nebulizers (USN):
    • Operating Principle: Uses an electrical power supply to drive a piezoelectric ceramic crystal transducer at high ultrasonic frequencies (1.0–2.5 MHz1.0\text{–}2.5\,\text{MHz}).
    • High-frequency acoustic vibrations travel through a sterile water coupling bath into a medication cup, creating localized oscillation waves on the fluid surface.
    • These surface waves break into a fountain (geyser) of small aerosol droplets.
    • Performance Characteristics: Nebulizer output and droplet density are controlled by electronic signal amplitude (power); droplet size is inversely related to acoustic vibration frequency (Frequency∝1/Particle Size\text{Frequency} \propto 1/\text{Particle Size}).
    • Clinical Use: Used to deliver bland aerosol therapy (hypertonic saline solutions) to induce diagnostic sputum production.
    • Limitations: Ultrasound vibrations transfer thermal energy into the liquid cup, degrading heat-labile proteins, peptides, and suspensions.

Ultrasonic nebulizer design and operation

  • Vibrating Mesh Nebulizers (VMN):
    • Active Vibrating Mesh Nebulizers (e.g., Aerogen Solo, PARI e-Flow):
    • Incorporate an aperture plate with thousands of funnel-shaped, laser-drilled micro-holes surrounded by a piezoelectric vibrational element.
    • High-frequency vibration (≈128 kHz\approx 128\,\text{kHz}) of the aperture plate pulls liquid through the micro-pores, extruding droplets into a low-velocity mist.
    • Passive Mesh Nebulizers (e.g., InnoSpire Go, i-Neb):
    • Utilize an ultrasonic horn to vibrate and push liquid medication through a stationary micro-perforated mesh plate.

Active and passive vibrating mesh nebulizers

  • Clinical Advantages of VMNs:

    • Minimal residual volume (0.1 mL to 0.4 mL0.1\,\text{mL}\text{ to } 0.4\,\text{mL}), reducing drug wastage.

    • Does not require external compressed gas, allowing in-line ventilator placement without altering delivered tidal volumes or ventilator flow triggers.

    • Capable of continuous infusion or intermittent delivery with syringe pumps.

    • Does not denature fragile pharmacological compounds or heat solutions.

    • Smart and Dosimetric Nebulizers:

  • High-efficiency devices combining mesh technology with microprocessor controls to optimize delivery and track patient compliance:

    • i-Neb Adaptive Aerosol Delivery (AAD): Analyzes patient inspiratory depth and timing, pulsing aerosol exclusively during the initial 50%50\% of inspiration. Used for prostacyclin analogues (Iloprost) to manage pulmonary arterial hypertension (PAH\text{PAH}).
    • Akita Smart Nebulizer: Controls inspiratory flow and volume via smart-card programmed parameters to target drug deposition to specific lung regions.
    • Cayston Altera eFlow System: Designed for delivering inhaled aztreonam to patients with cystic fibrosis.
    • Tyvaso Inhalation System: Ultrasonic dosimetric device designed specifically for inhaled Treprostinil.

Pressurized Metered-Dose Inhalers (pMDIs) and Soft Mist Inhalers (SMIs)

  • Physical Design and Functional Components:
    • Canister: Heavy-gauge aluminum alloy cylinder capable of withstanding internal pressures (≈400–500 kPa\approx 400\text{–}500\,\text{kPa}).
    • Propellant: Hydrofluoroalkane (HFA-134a or HFA-227), replacing chlorofluorocarbons (CFCs).
    • Formulation: Contains active micronized drug, propellant, and chemical surfactants/cosolvents (such as oleic acid, ethanol, or sorbitan trioleate) to prevent particle aggregation and lubricate the valve stem.
    • Metering Valve: Delivers a reproducible volume (20 μL to 100 μL20\,\mu\text{L}\text{ to } 100\,\mu\text{L}) with each actuation.
    • Actuator Boot and Nozzle: Encloses the canister; contains a nozzle orifice matched to the drug formulation to control plume velocity and droplet dispersion.
    • Integrated Dose Counters: Mandated by the FDA on modern pMDIs to track remaining doses; replaces unreliable visual checks or water-floatation methods.

Metered dose inhaler components and metering valve function

  • Priming Protocols:

    • Involves shaking the inhaler and discharging 1 to 41\text{ to } 4 test sprays into the air away from people.
    • Required when initiating a new inhaler or when an HFA inhaler has remained unused for more than 2 days2\,\text{days} (CFC inhalers required re-priming after 4 to 6 hours4\text{ to } 6\,\text{hours}).
  • Breath-Actuated pMDIs (e.g., QVAR RediHaler):

    • Incorporates an internal spring-loaded trigger activated by patient inspiratory airflow (>20–30 L/min>20\text{–}30\,\text{L/min}).
    • Fires automatically during inhalation, eliminating the need for hand-breath coordination.
    • Approved for patients aged 6 years6\,\text{years} and older.
  • Factors Influencing pMDI Drug Delivery:

    • Nozzle Cleanliness: Crystallized drug or lint obstructing the orifice alters plume geometry and reduces emitted dose.
    • Temperature: Cold canisters (<15∘C<15^\circ\text{C}) generate larger droplets with lower vapor pressures, reducing emitted dose. Canisters should be warmed to body temperature in the hands before use.
    • Actuation Interval: Firing multiple puffs without a pause causes canister cooling (latent heat of vaporization), increasing droplet size and reducing lung deposition. Providers recommend waiting 30 to 60 seconds30\text{ to } 60\,\text{seconds} between puffs (a minimum of 15 seconds15\,\text{seconds} is required for valve pressure recovery).
  • Step-by-Step pMDI Technique:

    • Warm canister in hands and shake vigorously.
    • Remove cap; check the mouthpiece and nozzle for foreign debris.
    • Prime the device if new or unused for >2 days>2\,\text{days}.
    • Open-Mouth Technique (Preferred for standalone pMDI without holding chamber): Position mouthpiece 4 cm4\,\text{cm} (22 finger-widths) in front of the open mouth with the canister oriented upright; keep the tongue flat.
    • Closed-Mouth Technique: Place mouthpiece securely between lips, maintaining an airtight seal with tongue depressed.
    • Exhale normally to functional residual capacity (FRC\text{FRC}).
    • Begin a slow, deep inhalation through the mouth (<0.5 L/s<0.5\,\text{L/s} or <30 L/min<30\,\text{L/min}) and actuate the inhaler once.
    • Continue slow inhalation to total lung capacity (TLC\text{TLC}).
    • Hold breath for up to 10 seconds10\,\text{seconds} (or as long as comfortable), then resume normal breathing.
    • Wait 30 to 60 seconds30\text{ to } 60\,\text{seconds} before administering subsequent actuations.
  • pMDI Accessory Devices:

    • Designed to resolve hand-breath dyssynchrony and reduce high oropharyngeal impaction (which reaches 80%80\% with standalone pMDIs).
    • Spacers: Simple, valveless extension tubes that increase the distance between the pMDI nozzle and oral cavity. Allows the high-velocity plume to decelerate and propellants to evaporate, capturing large ballistic droplets and reducing oral impaction.
    • Valved Holding Chambers (VHC, e.g., AeroChamber Z-STAT):
    • Incorporates a one-way inspiratory valve that opens only when the patient inhales and closes on exhalation.
    • Retains the aerosol cloud within the chamber for several seconds, allowing uncoordinated patients or young children to inhale the dose across 3 to 73\text{ to } 7 tidal breaths.
    • Available with pediatric silicone masks.
    • Constructed with anti-static polymers to prevent electrostatic charge from attracting charged aerosol particles to chamber walls.
    • Maintenance: Clean monthly with warm water and mild dishwashing liquid; air dry without towel-rubbing to preserve anti-static properties.

Spacers and valved holding chambers with masks

  • Common Canister Protocols in Inpatient Care:

    • Designed to reduce pharmacy costs (\200\text{–}\300300 per pMDI vs. pennies per nebulizer ampule).
    • The hospital assigns one pMDI canister to multiple patients, sterilizing the nozzle stem with alcohol and using a patient-dedicated valved holding chamber for each administration.
  • Soft Mist Inhalers (SMI, Respimat):

    • Propellant-free, handheld inhaler driven by an internal mechanical spring.
    • Turning the base compresses the spring; pressing the release button forces a metered drug volume through micro-machined capillary channels (Uniblock nozzle).
    • Emits a slow-moving, fine aerosol cloud lasting 1.5 seconds1.5\,\text{seconds}, reducing oropharyngeal impaction and improving lower airway deposition compared to standard pMDIs.

Dry Powder Inhalers (DPIs)

  • Mechanisms of Action:

    • Breath-actuated devices where patient inspiratory effort draws ambient air through finely milled micronized drug powder.
    • Uses lactose or glucose carrier sugar crystals bound to micronized active drug molecules. High internal turbulence created by patient inspiratory airflow shears drug particles from carrier crystals, generating a respirable aerosol.
    • Requires an inspiratory flow rate of at least 40 to 60 L/min40\text{ to } 60\,\text{L/min} (>60 L/min>60\,\text{L/min} optimal).
  • Device Design Categories:

    • Unit-Dose DPIs: Dispense single doses from individual gelatin capsules loaded manually into the chamber and pierced by external buttons before inhalation.
    • HandiHaler (Tiotropium / Spiriva for COPD).
    • Arcapta Neohaler (Indacaterol).
    • TOBI Podhaler (Tobramycin for cystic fibrosis).
    • Multiple Unit-Dose DPIs: Contain a pre-loaded wheel or disk containing sealed blister packs.
    • Diskhaler (Relenza / Zanamivir for influenza).
    • Multiple-Dose Reservoir DPIs: Store bulk drug in an internal reservoir; doses are metered via a twist mechanism or lever.
    • Diskus (Advair, Flovent).
    • Twisthaler (Asmanex / Mometasone).
    • Flexhaler (Pulmicort / Budesonide).
    • Pressair (Tudorza / Aclidinium).
    • Ellipta (Breo, Anoro, Incruse, Trelegy).
  • Factors Affecting Performance:

    • Internal Resistance and Peak Flow: High-resistance DPIs require greater patient inspiratory effort to generate the shear stresses needed for deaggregation. Patients with acute bronchospasm, severe neuromuscular disease, or age <4 years<4\,\text{years} often cannot achieve the required flow (≥40–60 L/min\ge 40\text{–}60\,\text{L/min}).
    • Humidity and Moisture Contamination: Moisture causes dry powder to aggregate into large clumps that cannot deaggregate or escape the device, reducing emitted dose.
    • Patients must never exhale into a DPI.
    • DPIs must not be stored in humid bathrooms or submerged in cleaning water.
  • Step-by-Step DPI Technique:

    • Prepare and prime the dose, holding the device upright according to manufacturer instructions.
    • Exhale smoothly to functional residual capacity (FRC\text{FRC}), turning the head away from the device.
    • Place the mouthpiece between the lips, establishing a tight seal without obstructing air intake vents.
    • Inhale forcefully and deeply (>60 L/min>60\,\text{L/min}) from the start of the breath.
    • Remove inhaler from mouth and hold breath for up to 10 seconds10\,\text{seconds}.
    • Check the device or capsule to confirm the full dose was evacuated; repeat inhalation if powder remains.

Clinical Selection of Aerosol Delivery Systems and Comparative Deposition

  • Device Selection by Patient Age Group:

    • Neonates and Infants (<1 year<1\,\text{year}): SVN with a contoured aerosol mask; Valved Holding Chamber with mask.
    • Toddlers (1 to 3 years1\text{ to } 3\,\text{years}): SVN with mask; VHC with mask.
    • Preschool Children (3 to 4 years3\text{ to } 4\,\text{years}): SVN with mouthpiece; VHC with mouthpiece.
    • Children (>4 years>4\,\text{years}): pMDI alone (if trained); Breath-Actuated Nebulizer (BAN); Dry Powder Inhaler (DPI).
    • Children (>6 years>6\,\text{years}) and Adults: Breath-actuated pMDI (e.g., RediHaler), DPI, SMI, or standalone pMDI.
  • Comparative Drug Deposition Profiles Across Devices:

    • Nebulizer (Standard Continuous Jet SVN):
    • Lung Deposition: ≈12%\approx 12\%.
    • Oropharyngeal Deposition: ≈2%\approx 2\%.
    • Device Loss (Dead Volume): ≈66%\approx 66\%.
    • Exhaled Loss: ≈20%\approx 20\%.
    • pMDI Alone (Poor Technique / Direct Mouthpiece):
    • Lung Deposition: ≈10%\approx 10\%.
    • Oropharyngeal Deposition: ≈80%\approx 80\%.
    • Device Loss: ≈9%\approx 9\%.
    • Exhaled Loss: ≈1%\approx 1\%.
    • pMDI with Simple Spacer:
    • Lung Deposition: ≈15%\approx 15\%.
    • Oropharyngeal Deposition: ≈10%\approx 10\%.
    • Device Loss: ≈74%\approx 74\%.
    • Exhaled Loss: ≈1%\approx 1\%.
    • pMDI with Non-Electrostatic Valved Holding Chamber (VHC):
    • Lung Deposition: ≈40%\approx 40\% (highest of all delivery modes).
    • Oropharyngeal Deposition: ≈1%\approx 1\%.
    • Device Loss: ≈57%\approx 57\%.
    • Exhaled Loss: ≈2%\approx 2\%.
    • Dry Powder Inhaler (DPI):
    • Lung Deposition: ≈18%\approx 18\%.
    • Oropharyngeal Deposition: ≈78%\approx 78\%.
    • Device Loss: ≈2%\approx 2\%.
    • Exhaled Loss: ≈2%\approx 2\%.

Aerosol deposition comparison across delivery devices

  • Decision Algorithm for Device Selection:
    • Determine whether an MDI formulation is available:
    • If yes, evaluate if the patient can use an MDI alone.
      • If yes and the drug is not a steroid: Prescribe MDI alone.
      • If the drug is an inhaled steroid: Prescribe MDI with a valved holding chamber.
    • If the patient cannot use an MDI alone, check for a breath-actuated MDI:
      • If available: Prescribe breath-actuated MDI.
      • If unavailable: Prescribe MDI with a valved holding chamber.
    • If an MDI is unavailable, evaluate if a DPI formulation exists:
    • Assess whether the patient can generate an inspiratory flow rate >40–60 L/min>40\text{–}60\,\text{L/min} and follow device instructions.
      • If yes: Prescribe DPI.
    • If a DPI is unavailable or patient flow is inadequate, assess if a liquid solution is available:
    • If solution is available, verify whether the drug nebulizes effectively:
      • If yes, determine if the medication is heat-labile:
      • If heat-labile: Use Small-Volume Nebulizer (SVN).
      • If not heat-labile: Ultrasonic Nebulizer (USN) or SVN may be used.
    • If no suitable solution exists, contact the physician to recommend a viable alternative formulation.

Aerosol drug delivery system selection algorithm

  • Clinical Factors Reducing Pulmonary Aerosol Deposition:
    • Presence of an artificial airway (endotracheal or tracheostomy tube) and invasive mechanical ventilation circuits.
    • Reduced airway caliber (pediatric, neonatal, or asthmatic airway remodeling).
    • Excessive gas flows and small tidal volumes with high respiratory rates.
    • Poor patient coordination and failure to achieve adequate inspiratory hold.

Patient Assessment, Monitoring Protocols, and Continuous Bronchodilator Therapy

  • Components of Comprehensive Bedside Assessment:

    • Patient Interview: Assess changes in dyspnea score and subjective perception of work of breathing.
    • Physical Observation: Monitor for accessory muscle recruitment, diaphoresis, cyanosis, and sputum volume/character.
    • Vital Signs: Track heart rate, blood pressure, respiratory rate, and continuous pulse oximetry (SpO2\text{SpO}_2).
    • Auscultation: Evaluate presence of bilateral air entry, inspiratory/expiratory wheezing, rhonchi, or a silent chest (indicating severe obstruction).
    • Bedside Pulmonary Function Testing: Track Peak Expiratory Flow (PEF\text{PEF}) and Percentage of Forced Expiratory Volume in 1 second1\,\text{second} (%FEV1\%\text{FEV}_1).
  • Assessment Frequency Guidelines:

    • Acute / Unstable Inpatient Setting:
    • Establish a complete pre-treatment baseline (PEF\text{PEF}, vital signs, breath sounds).
    • Perform assessments before and immediately after each intervention.
    • Maintain continuous SpO2\text{SpO}_2 monitoring.
    • Titrate dosage until the patient reaches 70% to 90%70\%\text{ to } 90\% of predicted or personal best PEF\text{PEF}, or symptoms resolve.
    • Stable Patient (Inpatient and Outpatient):
    • In-hospital: Measure PEF\text{PEF} before and after bronchodilator treatments; reduce to twice daily once stable.
    • Home care: Measure PEF\text{PEF} three to four times daily (upon rising, noon, late afternoon [4:00 PM–7:00 PM], and bedtime).
  • Continuous Bronchodilator Therapy (CBT) for Severe Exacerbations:

    • Indicated for refractory status asthmaticus where standard intermittent nebulization fails to reverse bronchospasm.
    • Dosing: Continuous nebulization of Albuterol at 10 mg/hr to 20 mg/hr10\,\text{mg/hr}\text{ to } 20\,\text{mg/hr}.
    • Apparatus Setup: Large-volume nebulizers (HEART, HOPE) with oxygen blenders or continuous infusion vibrating mesh systems (Aerogen with automated syringe pump).
    • Clinical Decision Algorithm:
    • Score clinical status at presentation.
    • If clinical score is <4<4: Administer standard Albuterol (2.5 mg2.5\,\text{mg} SVN or MDI + holding chamber 4 puffs4\,\text{puffs}); recheck in 1 hour1\,\text{hour}, then transition to every 4 hours4\,\text{hours} (Q4H\text{Q4H}) as needed.
    • If clinical score is >4>4: Escalate to SVN with undiluted Albuterol (8–20 breaths8\text{–}20\,\text{breaths}), SVN 2.5 mg2.5\,\text{mg} filled to 4–5 mL4\text{–}5\,\text{mL} every 20 minutes×3 doses20\,\text{minutes} \times 3\,\text{doses}, or MDI + holding chamber titrated to 12 puffs12\,\text{puffs}.
    • Reassess clinical score:
      • If score remains >4>4: Admit to an intensive care or monitored step-down unit and initiate Continuous Bronchodilator Therapy (CBT) at 15 mg/hr15\,\text{mg/hr}.
      • Place patient on continuous cardiorespiratory monitoring: EKG telemetry (arrhythmia detection), continuous SpO2\text{SpO}_2, and serum potassium (K+K^+) draws every 4 hours4\,\text{hours} to identify drug-induced hypokalemia.
      • Reassess score hourly; once the score falls below 44, titrate down to intermittent treatments.

Continuous bronchodilator therapy clinical decision algorithm

  • Off-Label Medication Delivery via Aerosol:
    • The administration of unapproved drugs (such as heparin for inhalation injury or intravenous antibiotics) via the aerosol route, or modifying standard device configurations.
    • Must be avoided when approved commercial inhalation formulations are available.
    • Requires written institutional policies, verified clinical dosing guidelines, and patient consent.